Free Newsletter
New FDA budget would top $4B
If President Obama gets his way on the FDA, the agency would see its federal funding rise by 6 percent to $2.51 billion. That means, together with user fees, the agency would have a total budget of $4 billion, allowing it to staff up by 1,251 additional full-time workers and fund a major expansion of its food-safety capabilities. A large chunk of it would fund regulation of tobacco.
The additional money would also be used to a.) Speed up review of generics, to get copycat drugs on the market sooner; b.) Review generic biologic drugs; and c.) Boost the safety of medical products, and the availability of data on their use. Some $100 million would be earmarked for safety initiatives; $25 million would be used to beef up FDA's science capabilities.
The FDA has been pumping up on the funding side for the last couple of years, after a long dry spell when budgets either shrank or stagnated. The push for additional drug-safety funding gathered steam after a series of snafus exposed vast holes in the agency's inspection coverage, particularly overseas. And the agency's own Science Board lambasted its scientific expertise and equipment. No word yet on just how much of the new budget would be funneled to international inspections and overseas FDA offices.
- read the FDA release
- see the Washington Post story
- get more from EU News Network
Related Articles:
GAO flogs FDA for lack of data
Obama wants to boost FDA budget 19%
Stimulus gives $1.1B to comparative studies
FDA finally gets long-awaited funds - FDA trends
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: